DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-711/S-019, S-020

GlaxoSmithKline
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

Attention: Mary E. Martinson
Director, Regulatory Affairs, Psychiatry

Dear Ms. Martinson:

Please refer to your supplemental new drug applications dated April 30 and May 13, 2004, received May 3 and 14, 2004, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ZYBAN (bupropion hydrochloride).

Reference is also made to your submission dated September 30, 2004 (S-019).

Supplement S-019, submitted as "Changes Being Effected" supplement in response to the Agency's letters dated March 19 and April 19, 2004, provides for revised **WARNINGS** and **PRECAUTIONS** sections of the package insert to warn prescribers, patients and their families of the need for close observation of patients being treated with antidepressants for clinical worsening, for the emergence of suicidality, and for the emergence of a variety of other symptoms that may represent a precursor to suicidality, regardless of the role antidepressants may have in the emergence of suicidal ideation/attempts in patients taking antidepressants.

Supplement S-020 provides for a revised immediate container labels. The text "Twice-a-Day [After Initial Titration]" is added.

We have completed our review of these supplemental applications, as amended, and they are approved, effective on the date of this letter.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Pratibha Rana, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, M.D.
Director
Division of Anesthetic, Critical Care,
and Addiction Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bob Rappaport

11/3/04 04:58:39 PM